CLEARWATER, FL — March 29, 2018 – Bovie Medical Corporation (NYSEMKT:BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma^®, a patented surgical product, today announced the launch of Renuvion™, a new brand that is dedicated to the cosmetic surgery market.

Bovie Medical’s J-Plasma technology will now be marketed and sold in the cosmetic surgery market under the brand name, Renuvion. The Renuvion brand will be marketed as a cosmetic technology and will feature its own distinct logo, website and promotional materials. The Company has also adopted two taglines related to the Renuvion brand: Reshaping What’s Possible™ and What will you renu?™

“On behalf of Bovie Medical, I am excited to announce the launch of the Renuvion brand, which we have developed as part of our commitment to enhancing our ability to commercialize our J-Plasma technology in the cosmetic surgery market,” said Charlie Goodwin, Chief Executive Officer. “The Renuvion brand – and its taglines: Reshaping What’s Possible and What will you renu? – represent the potential that we see for our transformational J-Plasma technology to positively impact physician practices and the lives of their patients. Most importantly, Renuvion was created specifically for physicians in the cosmetic surgery market, including plastic surgeons, cosmetic surgeons and dermatologists, who will be able to leverage the increasing awareness of this brand as we establish Bovie Medical as a provider of innovative technologies in this market.”

Those interested in learning more are encouraged to visit: https://www.Renuvion.com/

Investor Relations Contact:

Westwicke Partners on behalf of Bovie Medical Corporation
Mike Piccinino, CFA
443-213-0500
investor.relations@boviemed.com

About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of plasma that provides surgeons with greater precision, and minimal invasiveness. The new J-Plasma® handpieces with Cool-Coag™ technology deliver the precision of helium plasma energy, the power of traditional monopolar coagulation and the efficiency of plasma beam coagulation – enabling thin-layer ablation and dissection and fast coagulation with a single instrument, minimizing instrument exchange and allowing a surgeon to focus on their patient and their procedures. With Cool-Coag technology, the new J-Plasma handpieces can deliver three distinctly different energy modalities – further increasing the utility and versatility of the J-Plasma system. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, IDS™ and DERM™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation at www.boviemedical.com.

Cautionary Statement on Forward-Looking Statements:

Certain matters discussed in this release and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the Company’s ability to control or predict. Important factors that may cause actual results to differ materially and that could impact the Company and the statements contained in this release can be found in the Company’s filings with the Securities and Exchange Commission including the Company’s Report on Form 10-K for the year ended December 31, 2016 and subsequent Form 10-Q filings. For forward-looking statements in this release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.